HULL, England -- Smith & Nephew's Advanced Wound Management division announces today the signing of an exclusive worldwide sales, marketing and distribution
agreement with Covalon Technologies for its advanced range of collagen dressings. Smith & Nephew Advanced Wound Management will be the sole distributor of ColActive(TM) products globally, effectively immediately. The agreement not only allows the distribution of ColActive(TM) range of products based on Covalon's unique patented technology, but also grants access and distribution rights to a differentiated new product development portfolio in the field of advanced wound care utilizing the same unique technology. This will yield further new product introductions in 2007. This agreement further strengthens the Smith & Nephew Advanced Woundcare product portfolio alongside our ALLEVYN* foam and ACTICOAT* antimicrobial technologies and offers customers a more comprehensive solution to address their wound care needs.
"The addition of the Covalon collagen dressing range truly strengths the Smith & Nephew product portfolio and the obvious synergies between the two companies also look set to deliver exciting future new product development opportunities in addition to the current distributed products," said Roger Teasdale, senior vice president of the Advanced Woundcare Strategic Business Unit.
Joe Woody, president of Smith & Nephew Advanced Wound Management, said, "This is an important entry into a fast growing product category and reinforces our strategic focus on the U.S. The Covalon agreement is in line with our strategy to aggressively acquire or partner, enabling access to advanced technologies that deliver true patients benefits and shareholder value."
Source: Smith & Nephew
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Understanding NHSN's 2022 Rebaseline Data: Key Updates and Implications for HAI Reporting
December 13th 2024Discover how the NHSN 2022 Rebaseline initiative updates health care-associated infection metrics to align with modern health care trends, enabling improved infection prevention strategies and patient safety outcomes.
Tackling Health Care-Associated Infections: SHEA’s Bold 10-Year Research Plan to Save Lives
December 12th 2024Discover SHEA's visionary 10-year plan to reduce HAIs by advancing infection prevention strategies, understanding transmission, and improving diagnostic practices for better patient outcomes.
Expanded Screening Protocols Improve Early Detection of Candida auris at Mount Sinai Brooklyn
December 1st 2024Mount Sinai Brooklyn’s expanded Candida auris screening protocols identified more cases, enabling timely isolation and disinfection measures to prevent outbreaks and enhance patient safety in hospital settings.